Table 1. Baseline characteristics of enrolled studies.

Study	Type	Time (published)	Country	Jadad scale (randomization + concealment of allocation + double blinding + withdrawals and dropouts)	Participant	Age (A vs. B)	Male/total (A vs. B)	Total number (A vs. B)	Mortality (A vs. B)	A; B
Annane et al.	RCT	2007	France	1+1+1+0=3	Multi-center	–	–	161; 169	64; 58	Epinephrine; norepinephrine+ dobutamine
Baske et al.	RCT	2018	India	2+2+2+1=7	One center	–	14/20; 13/20	20; 20	14; 16	Epinephrine; dopamine
Choudhury et al.	RCT	2017	India	2+2+0+1=5	One center	46.76±12.11; 48.29±12.53	35/42; 34/42	42; 42	32; 36	Terlipressin; norepinephrine
De Backer et al.	RCT	2010	Spain	2+2+0+1=5	Multi-center	–	–	542; 502	291; 249	Dopamine; norepinephrine
Gordon et al.	RCT	2016	United Kingdom	2+2+2+1=7	Multi-center	–	111/204; 127/204	204; 204	63; 56	Vasopressin; norepinephrine
Gordon et al.	RCT	2010	Canada	1+1+1+1=4	Multi-center	–	–	397; 382	140; 150	Vasopressin; norepinephrine
Hammond et al.	RCT	2018	France	1+1+0+0=2	One center	62 [51–74]; 60 [49–68]	22/41; 18/41	41; 41	19; 18	Vasopressin + norepinephrine; norepinephrine
Hua et al.	RCT	2013	China	2+1+0+0=3	One center	52.2±14.0; 56.6±16.4	8/16; 10/16	16; 16	8; 7	Dopamine; terlipressin
Jain et al.	RCT	2010	India	2+1+2+0=5	One center	42.88±5.39; 45.29±7.41	15/27; 13/27	27; 27	15; 16	Norepinephrine; phenylephrine
Levy et al.	RCT	1997	France	1+1+0+0=2	One center	54±10; 56±9	10/15; 11/15	15; 15	9; 8	Epinephrine; norepinephrine+ dobutamine
Lauzier et al.	RCT	2006	Canada	2+2+0+0=4	Two centers	58.1±17.5; 51.2±17.2	8/10; 6/13	10; 13	3; 3	Norepinephrine; vasopressin
Luckner et al.	RCT	2006	Austria	1+1+0+0=2	One center	–	–	10; 8	8; 7	Vasopressin + norepinephrine; norepinephrine
Marik et al.	RCT	1994	–	–	One center	–	–	10; 10	5; 6	Norepinephrine; dopamine
Mathur et al.	RCT	2007	–	–	One center	–	–	25; 25	14; 19	Norepinephrine; dopamine
Martin et al.	RCT	1993	–	–	One center	–	–	16; 16	7; 10	Norepinephrine; dopamine
Morelli et al.	RCT	2008	Italy	2+1+0+1=4	One center	70 [53–74]; 70 [59–74]	11/14; 13/19	16; 16	10; 9	Phenylephrine; norepinephrine
Morelli et al.	RCT	2008	Italy	1+1+0+1=3	One center	66 [28–84]; 67 [29–83]	13/19; 14/20	19; 20	12; 14	Terlipressin; norepinephrine
Morelli et al.	RCT	2009	Italy	2+1+0+1=4	One center	67 [60–71]; 66 [60–74]; 64 [59–72]	11/15; 10/15; 12/10	15; 15; 15	7; 8; 10	Terlipressin; vasopressin; norepinephrine
Myburgh et al.	RCT	2008	Australia	2+2+2+1=7	Mult-center	59.4±15.9; 60.4±14.8	10/64; 7/63	64; 63	15; 17	Epinephrine; norepinephrine
Mahmoud et al.	RCT	2012	Egypt	2+2+2+0=6	One center	52.4±4.5; 50.3±6.5	16/30; 15/30	30; 30	15; 16	Norepinephrine + dobutamine; norepinephrin + epinephrine
Mehta et al.	RCT	2013	Canada	1+1+1+1=4	9 centers	62.9 [51.2–73.6]; 65.5 [50.8–76.1]	43/65; 42/56	65; 56	27; 24	Vasopressin; norepinephrine
Patel et al.	RCT	2010	USA	1+1+0+0=2	One center	–	64/134; 52/118	134; 118	67; 51	Dopamine; norepinephrine
Ruokonen et al.	RCT	1993	Finland	1+1+0+0=2	One center	18-76; 39–53	–	5; 5	4; 3	Norepinephrine; dopamine
Ramaswamy et al.	RCT	2016	India	2+2+2+1=7	One center	7 [1–11]; 4 [0.8–8]	15/29; 15/31	29; 31	14; 18	Epinephrine; dopamine
Russell et al.	RCT	2009	Australia	1+1+1+1=4	Mult-center	–	–	396; 382	140; 150	Vasopressin; norepinephrine
Russell et al.	RCT	2008	Canada	2+2+2+1=7	Mult-center	59.3±16.4; 61.8±16	246/396; 229/382	396; 382	140; 150	Vasopressin; norepinephrine
Russell et al.	RCT	2013	Canada	1+1+1+0=3	Multi-center	60.7±16.7; 60.0±15.7	121/191; 112/203	191; 203	65; 60	Norepinephrine; vasopressin
Schmoelz et al.	RCT	2006	Germany	2+1+2+0=2	One center	49.24±19.03; 56.7±18.5	14/22; 10/21	22; 21	4; 5	Dopamine; dopexamine
Seguin et al.	RCT	2002	France	1+1+0+0=2	One center	65±12; 70±13	6/10; 6/11	10; 11	4; 5	Epinephrine; norepinephrine+ dobutamine
Seguin et al.	RCT	2006	France	1+1+0+0=2	One center	67±13; 65±10	–	10; 12	3; 2	Epinephrine; dopexamine + norepinephrine
Ventura et al.	RCT	2015	Brazil	2+2+2+1=7	One center	39.6±46.3 months; 56.9±58.2 months	35/63; 35/57	63; 57	13; 4	Dopamine; epinephrine

RCT, randomized controlled trial.